[go: up one dir, main page]

WO2002055688A8 - Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms - Google Patents

Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms

Info

Publication number
WO2002055688A8
WO2002055688A8 PCT/US2002/000714 US0200714W WO02055688A8 WO 2002055688 A8 WO2002055688 A8 WO 2002055688A8 US 0200714 W US0200714 W US 0200714W WO 02055688 A8 WO02055688 A8 WO 02055688A8
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid
histone deacetylase
cells
expression
thyroid cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000714
Other languages
French (fr)
Other versions
WO2002055688A3 (en
WO2002055688A2 (en
Inventor
Antonio Tito Fojo
Susan Elaine Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to EP02718823A priority Critical patent/EP1356053A2/en
Priority to CA002434269A priority patent/CA2434269A1/en
Priority to US10/250,320 priority patent/US20040132643A1/en
Priority to JP2002556736A priority patent/JP2005507231A/en
Priority to AU2002249938A priority patent/AU2002249938B2/en
Publication of WO2002055688A2 publication Critical patent/WO2002055688A2/en
Publication of WO2002055688A3 publication Critical patent/WO2002055688A3/en
Publication of WO2002055688A8 publication Critical patent/WO2002055688A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and/or the Na+/I- symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biologically aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and/or the Na+/I- symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.
PCT/US2002/000714 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms Ceased WO2002055688A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02718823A EP1356053A2 (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
CA002434269A CA2434269A1 (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
US10/250,320 US20040132643A1 (en) 2002-01-09 2002-01-09 Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
JP2002556736A JP2005507231A (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in the diagnosis and treatment of thyroid neoplasms
AU2002249938A AU2002249938B2 (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26073301P 2001-01-10 2001-01-10
US60/260,733 2001-01-10

Publications (3)

Publication Number Publication Date
WO2002055688A2 WO2002055688A2 (en) 2002-07-18
WO2002055688A3 WO2002055688A3 (en) 2003-04-10
WO2002055688A8 true WO2002055688A8 (en) 2003-09-25

Family

ID=22990378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000714 Ceased WO2002055688A2 (en) 2001-01-10 2002-01-09 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms

Country Status (5)

Country Link
EP (1) EP1356053A2 (en)
JP (1) JP2005507231A (en)
AU (1) AU2002249938B2 (en)
CA (1) CA2434269A1 (en)
WO (1) WO2002055688A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227136A1 (en) * 2002-06-18 2004-01-29 Loos, Ulrich, Prof. Dr.med. Compositions containing thiazolidinediones and their use
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006520796A (en) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
JP2008524246A (en) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
JP2008540574A (en) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1996233A2 (en) * 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
MX342913B (en) 2010-07-12 2016-10-19 Celgene Corp * Romidepsin solid forms and uses thereof.
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071703A2 (en) * 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy

Also Published As

Publication number Publication date
JP2005507231A (en) 2005-03-17
AU2002249938B2 (en) 2006-12-21
EP1356053A2 (en) 2003-10-29
CA2434269A1 (en) 2002-07-18
WO2002055688A3 (en) 2003-04-10
WO2002055688A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
WO2002055688A8 (en) Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
Shabani et al. Enhancement of wound repair with a topically applied nitric oxide‐releasing polymer
ATE387191T1 (en) CHEWABLE SOFT CAPSULE
SG147485A1 (en) Pharmaceutical compositions for prevention of overdose or abuse
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BRPI0412885A (en) polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents
NZ512219A (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
SG165998A1 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
DK1401422T3 (en) Halogen-containing composition, process for its preparation and uses thereof
BR0316550A (en) Compound, pharmaceutical composition, and methods for treating or preventing cancer in a patient, and for detecting cancer in a patient
Al-Otaibi et al. Ameliorative potential of stem bromelain on lead-induced toxicity in Wistar rats
EA200200502A1 (en) METHOD OF INTRODUCTION OF PHOSPHODYSTRASE 4 INHIBITOR
Huang et al. Heterochromatic proteins specifically enhance nickel-induced 8-oxo-dG formation
UA81634C2 (en) Pharmaceutical compoosition containing urease for inhibiting cancer cell growth
Joshi et al. Scavenging action of zinc and green tea polyphenol on cisplatin and nickel induced nitric oxide generation and lipid peroxidation in rats
MA27099A1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL
PT1509523E (en) Triazaspiro compounds useful for treating or preventing pain
JP2009125624A (en) Insolubilization method of heavy metal-contaminated ground
WO2006103494A3 (en) Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
DE60327173D1 (en) COMPREHENSIVE MEDICAMENTS FOR CANCER TREATMENT WITH A SEROTONIN TRANSPORTER
ATE385798T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING AZD 2171 AND ZD 6126 AND USES
EA200401454A1 (en) NEW COMBINATION FROM REVERSIBLE ACTING PROTONE PUMP INHIBITORS AND USED IN THE THERAPY OF RESPIRATORY WAYS OF MEDICINAL SUBSTANCES FOR THE TREATMENT OF RESPIRATORY DISEASES
Xu et al. Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2, 2-dimethyl-[1, 3] dithiolane-4-carboxylic acids
Gebhardt et al. Determination of ascorbic acid by isotachophoresis with regard to its potential in neuroblastoma therapy
Roopnarinsingh et al. The effect of cysteine analogues on the excretion of urinary sulphate in the rat following cysteine administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002249938

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434269

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002556736

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002718823

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2002 UNDER (22) REPLACE "8 JANUARY 2002 (08.01.2002)" BY "9 JANUARY 2002 (09.01.2002)"

WWP Wipo information: published in national office

Ref document number: 2002718823

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10250320

Country of ref document: US